These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 23108952)

  • 1. Bevacizumab with peri-operative epirubicin, cisplatin and capecitabine (ECX) in localised gastro-oesophageal adenocarcinoma: a safety report.
    Okines AF; Langley RE; Thompson LC; Stenning SP; Stevenson L; Falk S; Seymour M; Coxon F; Middleton GW; Smith D; Evans L; Slater S; Waters J; Ford D; Hall M; Iveson TJ; Petty RD; Plummer C; Allum WH; Blazeby JM; Griffin M; Cunningham D
    Ann Oncol; 2013 Mar; 24(3):702-9. PubMed ID: 23108952
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Peri-operative chemotherapy with or without bevacizumab in operable oesophagogastric adenocarcinoma (UK Medical Research Council ST03): primary analysis results of a multicentre, open-label, randomised phase 2-3 trial.
    Cunningham D; Stenning SP; Smyth EC; Okines AF; Allum WH; Rowley S; Stevenson L; Grabsch HI; Alderson D; Crosby T; Griffin SM; Mansoor W; Coxon FY; Falk SJ; Darby S; Sumpter KA; Blazeby JM; Langley RE
    Lancet Oncol; 2017 Mar; 18(3):357-370. PubMed ID: 28163000
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A phase II trial of preoperative chemotherapy with epirubicin, cisplatin and capecitabine for patients with localised gastro-oesophageal junctional adenocarcinoma.
    Starling N; Okines A; Cunningham D; Allum W; Wotherspoon A; Benson M; Thompson J; Thomas J; Brown G; Riddell A; Stavridi F; Ashley S; Oates J; Chau I
    Br J Cancer; 2009 Jun; 100(11):1725-30. PubMed ID: 19436301
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Matuzumab plus epirubicin, cisplatin and capecitabine (ECX) compared with epirubicin, cisplatin and capecitabine alone as first-line treatment in patients with advanced oesophago-gastric cancer: a randomised, multicentre open-label phase II study.
    Rao S; Starling N; Cunningham D; Sumpter K; Gilligan D; Ruhstaller T; Valladares-Ayerbes M; Wilke H; Archer C; Kurek R; Beadman C; Oates J
    Ann Oncol; 2010 Nov; 21(11):2213-2219. PubMed ID: 20497967
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Histopathological regression after neoadjuvant docetaxel, oxaliplatin, fluorouracil, and leucovorin versus epirubicin, cisplatin, and fluorouracil or capecitabine in patients with resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4-AIO): results from the phase 2 part of a multicentre, open-label, randomised phase 2/3 trial.
    Al-Batran SE; Hofheinz RD; Pauligk C; Kopp HG; Haag GM; Luley KB; Meiler J; Homann N; Lorenzen S; Schmalenberg H; Probst S; Koenigsmann M; Egger M; Prasnikar N; Caca K; Trojan J; Martens UM; Block A; Fischbach W; Mahlberg R; Clemens M; Illerhaus G; Zirlik K; Behringer DM; Schmiegel W; Pohl M; Heike M; Ronellenfitsch U; Schuler M; Bechstein WO; Königsrainer A; Gaiser T; Schirmacher P; Hozaeel W; Reichart A; Goetze TO; Sievert M; Jäger E; Mönig S; Tannapfel A
    Lancet Oncol; 2016 Dec; 17(12):1697-1708. PubMed ID: 27776843
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rilotumumab in combination with epirubicin, cisplatin, and capecitabine as first-line treatment for gastric or oesophagogastric junction adenocarcinoma: an open-label, dose de-escalation phase 1b study and a double-blind, randomised phase 2 study.
    Iveson T; Donehower RC; Davidenko I; Tjulandin S; Deptala A; Harrison M; Nirni S; Lakshmaiah K; Thomas A; Jiang Y; Zhu M; Tang R; Anderson A; Dubey S; Oliner KS; Loh E
    Lancet Oncol; 2014 Aug; 15(9):1007-18. PubMed ID: 24965569
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase I study of epirubicin, cisplatin and capecitabine plus matuzumab in previously untreated patients with advanced oesophagogastric cancer.
    Rao S; Starling N; Cunningham D; Benson M; Wotherspoon A; Lüpfert C; Kurek R; Oates J; Baselga J; Hill A
    Br J Cancer; 2008 Sep; 99(6):868-74. PubMed ID: 19238629
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of perioperative FLOT versus ECF/ECX on short-term outcomes after surgery for resectable oesophagogastric adenocarcinoma: propensity score-matched study.
    Moussa O; Bhogal RH; Malietzis G; Fribbens C; Starling N; Gerlinger M; Watkins D; Chau I; Rao S; Cunningham D; Allum WH; Chaudry A; Kumar S
    BJS Open; 2022 Jan; 6(1):. PubMed ID: 35195263
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Trastuzumab for the treatment of HER2-positive metastatic adenocarcinoma of the stomach or gastro-oesophageal junction.
    Norman G; Rice S; Spackman E; Stirk L; Danso-Appiah A; Suh D; Palmer S; Eastwood A
    Health Technol Assess; 2011 May; 15 Suppl 1():33-42. PubMed ID: 21609651
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prospective, randomized, multicenter, phase III study of fluorouracil, leucovorin, and irinotecan versus epirubicin, cisplatin, and capecitabine in advanced gastric adenocarcinoma: a French intergroup (Fédération Francophone de Cancérologie Digestive, Fédération Nationale des Centres de Lutte Contre le Cancer, and Groupe Coopérateur Multidisciplinaire en Oncologie) study.
    Guimbaud R; Louvet C; Ries P; Ychou M; Maillard E; André T; Gornet JM; Aparicio T; Nguyen S; Azzedine A; Etienne PL; Boucher E; Rebischung C; Hammel P; Rougier P; Bedenne L; Bouché O
    J Clin Oncol; 2014 Nov; 32(31):3520-6. PubMed ID: 25287828
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A randomised phase II study of combination chemotherapy with epirubicin, cisplatin and capecitabine (ECX) or cisplatin and capecitabine (CX) in advanced gastric cancer.
    Yun J; Lee J; Park SH; Park JO; Park YS; Lim HY; Kang WK
    Eur J Cancer; 2010 Mar; 46(5):885-91. PubMed ID: 20060288
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial.
    Al-Batran SE; Homann N; Pauligk C; Goetze TO; Meiler J; Kasper S; Kopp HG; Mayer F; Haag GM; Luley K; Lindig U; Schmiegel W; Pohl M; Stoehlmacher J; Folprecht G; Probst S; Prasnikar N; Fischbach W; Mahlberg R; Trojan J; Koenigsmann M; Martens UM; Thuss-Patience P; Egger M; Block A; Heinemann V; Illerhaus G; Moehler M; Schenk M; Kullmann F; Behringer DM; Heike M; Pink D; Teschendorf C; Löhr C; Bernhard H; Schuch G; Rethwisch V; von Weikersthal LF; Hartmann JT; Kneba M; Daum S; Schulmann K; Weniger J; Belle S; Gaiser T; Oduncu FS; Güntner M; Hozaeel W; Reichart A; Jäger E; Kraus T; Mönig S; Bechstein WO; Schuler M; Schmalenberg H; Hofheinz RD;
    Lancet; 2019 May; 393(10184):1948-1957. PubMed ID: 30982686
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neoadjuvant cisplatin and fluorouracil versus epirubicin, cisplatin, and capecitabine followed by resection in patients with oesophageal adenocarcinoma (UK MRC OE05): an open-label, randomised phase 3 trial.
    Alderson D; Cunningham D; Nankivell M; Blazeby JM; Griffin SM; Crellin A; Grabsch HI; Langer R; Pritchard S; Okines A; Krysztopik R; Coxon F; Thompson J; Falk S; Robb C; Stenning S; Langley RE
    Lancet Oncol; 2017 Sep; 18(9):1249-1260. PubMed ID: 28784312
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Report of two protocol planned interim analyses in a randomised multicentre phase III study comparing capecitabine with fluorouracil and oxaliplatin with cisplatin in patients with advanced oesophagogastric cancer receiving ECF.
    Sumpter K; Harper-Wynne C; Cunningham D; Rao S; Tebbutt N; Norman AR; Ward C; Iveson T; Nicolson M; Hickish T; Hill M; Oates J
    Br J Cancer; 2005 Jun; 92(11):1976-83. PubMed ID: 15928658
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bevacizumab plus capecitabine and cisplatin in Chinese patients with inoperable locally advanced or metastatic gastric or gastroesophageal junction cancer: randomized, double-blind, phase III study (AVATAR study).
    Shen L; Li J; Xu J; Pan H; Dai G; Qin S; Wang L; Wang J; Yang Z; Shu Y; Xu R; Chen L; Liu Y; Yu S; Bu L; Piao Y
    Gastric Cancer; 2015 Jan; 18(1):168-76. PubMed ID: 24557418
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Randomized prospective phase II study to compare the combination chemotherapy regimen epirubicin, cisplatin, and 5-fluorouracil with epirubicin, cisplatin, and capecitabine in patients with advanced or metastatic gastric cancer.
    Ocvirk J; Reberšek M; Skof E; Hlebanja Z; Boc M
    Am J Clin Oncol; 2012 Jun; 35(3):237-41. PubMed ID: 21399488
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adding preoperative radiotherapy plus cetuximab to perioperative chemotherapy for resectable esophageal adenocarcinoma: a single-center prospective phase II trial.
    Ubink I; van der Sluis P; Schipper M; Reerink O; Voest E; Borel-Rinkes I; Wijrdeman H; Vleggaar F; Agterof M; Overkleeft E; Siersema P; van Hillegersberg R; Lolkema MP
    Oncologist; 2014 Jan; 19(1):32-3. PubMed ID: 24335595
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rilotumumab plus epirubicin, cisplatin, and capecitabine as first-line therapy in advanced MET-positive gastric or gastro-oesophageal junction cancer (RILOMET-1): a randomised, double-blind, placebo-controlled, phase 3 trial.
    Catenacci DVT; Tebbutt NC; Davidenko I; Murad AM; Al-Batran SE; Ilson DH; Tjulandin S; Gotovkin E; Karaszewska B; Bondarenko I; Tejani MA; Udrea AA; Tehfe M; De Vita F; Turkington C; Tang R; Ang A; Zhang Y; Hoang T; Sidhu R; Cunningham D
    Lancet Oncol; 2017 Nov; 18(11):1467-1482. PubMed ID: 28958504
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Thromboembolism in patients with advanced gastroesophageal cancer treated with anthracycline, platinum, and fluoropyrimidine combination chemotherapy: a report from the UK National Cancer Research Institute Upper Gastrointestinal Clinical Studies Group.
    Starling N; Rao S; Cunningham D; Iveson T; Nicolson M; Coxon F; Middleton G; Daniel F; Oates J; Norman AR
    J Clin Oncol; 2009 Aug; 27(23):3786-93. PubMed ID: 19398575
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A phase I and pharmacokinetic study of capecitabine in combination with epirubicin and cisplatin in patients with inoperable oesophago-gastric adenocarcinoma.
    Evans TR; Pentheroudakis G; Paul J; McInnes A; Blackie R; Raby N; Morrison R; Fullarton GM; Soukop M; McDonald AC
    Ann Oncol; 2002 Sep; 13(9):1469-78. PubMed ID: 12196374
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.